Updates in the Treatment of HR+ Breast Cancer - Episode 9
Treatment Advancements Targeting the PI3K/AKT Pathway in HR+ Breast Cancer
A panel of experts discuss treatment advancements targeting the PI3K/AKT pathway in HR+ Breast Cancer.
Video content above is prompted by the following:
- What are the other options for advanced HR+ disease(PI3K/AKT/mTOR inhibitors)?
- When and how are these being used? Are there any AEs of concern? How do you manage?
- ADCs